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Abstract 
This study presents a simple but sensitive HPLC chromatographic method with a stability-
indicating assay for determination and physicochemical characterisation of L-carnosine, a 
promising senile cataract prophylactic agent. Chromatographic analysis was conducted using 
a reverse phase (RP)-HPLC system and an isocratic mobile phase of 98% v/v trifluoroacetic 
acid (0.1% v/v) and 2% v/v acetonitrile with detection at 220 nm. L-carnosine was subjected 
to stress conditions to force its degradation using chemical and thermal agents and was 
subsequently detected from its degradation products using ESI-MS. The lipophilicity of the 
drug and 1:1 drug to phospholipid complex (PC) mol/mol was determined by estimating the 
partition coefficient (P). Lipophilicity was greatly enhanced when L-carnosine was 
formulated as a phospholipid complex using the solvent evaporation method. L-carnosine-
phospholipid complex could be a promising approach for effective delivery to the human lens 
as offers a potential novel treatment for senile cataract. 
Key words 
L-carnosine, senile cataract, histidine, dipeptide, ocular delivery 
3 
 
Correspondence  
Hamdy Abdelkader, School of Pharmacy and Chemistry, Kingston University London, UK; 
h.abdelkader@kingston.ac.uk , +447440702427 
1. Introduction 
L-carnosine is an endogenous dipeptide (β-alanyl-L-histidine) found in skeletal muscles and 
nervous tissues in concentrations of 2-25 mM [1, 2]. Human plasma levels of L-carnosine 
have been reported to rise from levels that cannot be detected to 32 µg/ml as a result of meat 
consumption [2]. L-carnosine has been found to be a bioactive dipeptide; it possesses anti-
ageing properties which may have application in the treatment of senile cataract [3, 4]. The 
exact mechanism of how L-carnosine exerts these therapeutic benefits is not clearly known, 
but  it has been suggested that the mechanism can be attributed to potential antioxidant 
properties and the ability to scavenge free radicals accumulated as a consequence of ageing 
[5]. This role has yet to be confirmed. It has also been proposed that L-carnosine has a 
potential anti-gylcation effect, inhibiting or reducing the formation of advanced glycation end 
products responsible for age-related conditions such as Alzheimer’s [6], skin wrinkling [3] 
and senile cataracts [4]. Glycation end products result when glucose/reducing sugar moieties 
react to form amide bonds with the amino groups of proteins (e.g. those found in myelin, 
collagen and crystallins). The dipeptide carnosine has been found to inhibit the formation of 
protein carbonyls and cross-linking induced by reducing sugars and reactive aldehyde 
species, a mechanism termed  carnosinylation [7]. The role of L-carnosine in reversing or 
delaying the onset of senile cataracts is a promising area for further research [8]. Similar to 
histidine dipeptides, L-carnosine has very weak chromophores that would hamper direct and 
sensitive spectrophotometric detection. Histidine dipeptides have to be coupled with dyes 
such as p-bromoaniline and 2,4-dinitro-1-fluorobenzene to form coloured derivatives to allow 
quantitative detection [9]. However, this approach lacks the sensitivity and reproducibility 
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needed for routine analysis.  Reverse phase-HPLC methods were developed to quantify L-
carnosine using 100 mM phosphate buffer, pH 2 as mobile phase and UV detection at 210 nm 
[10, 11]. These conditions are problematic as they can shorten the life span of the reversed-
phase column system used, since it is devoid of any organic phase (e.g. acetonitrile) and the 
low pH of 2 coupled with a high inorganic salt concentration (100 mM of phosphate buffer) 
is likely to block ferules, automatic samplers and be detrimental to the HPLC system and 
hence produce poor yields. This problem has been tackled with the advent of novel polymeric 
based supports that graft the reverse hydrophobic moieties onto stationary phase rendering it 
more resistant to acidic conditions. 
In this study, a simple, sensitive, stable and rapid HPLC method was developed and validated 
according to the guidelines of International Conference on Harmonisation (ICH). The 
physicochemical properties of L-carnosine, in particular its chemical stability in solution and 
partition coefficient were investigated. The ability of the dipeptide drug (L-carnosine) to form 
a complex with a phospholipid in an attempt to alter its n-octanol / water partition coefficient 
and potentially improve its trans-corneal flux was investigated.   
2. Materials and methods 
2.1. Materials 
L-carnosine and L-histidine were purchased from Sigma-Aldrich, Dorset, England, the UK. 
β-alanine was purchased from BDH Biochemicals, Poole, England. Lipoid S75 was donated 
by Lipoid GmbH, Ludwigshafen, Germany. 1,4-dioxane and hydrogen peroxide were 
purchased from Fisher Scientific, Loughborough, UK. All other chemical and reagents were 
of analytical grade and used as received. 
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2.2. High performance liquid chromatography (HPLC) method development 
An HPLC system (Shimadzu LC-2010AHT, Shimadzu corporation, Kyoto, Japan) 
comprising a quaternary pump, an automatic sampler and a UV detector with data acquisition 
was used. The chromatographic separation was achieved using a Supelcosil C18 column (5 
µm; 250 mm×4.6 mm, Supelco Corporation, PA, USA) maintained at 40◦C. The mobile 
phase comprised trifluoroacetic acid (TFA) (0.1%) (98% v/v) and acetonitrile (2 % v/v). The 
isocratic flow rate was 1.0 ml/min and the injection volume was fixed at 30 µl. Detection was 
by UV absorbance at a wavelength of 220 nm.  
2.2.1. Validation of the HPLC analytical method  
The method was validated according to International Conference on Harmonisation (ICH) 
guidelines [12] .  Approximately 10 mg of carnosine were accurately weighed, transferred 
into a 10 ml volumetric flask and dissolved in deionised water to produce a stock solution of 
1mg/ml. Calibration standards were prepared by serial dilution using TFA (0.1% v/v) in the 
concentration range of 10 to 100 µg/ml. 
 Precision and accuracy 
Intra-day and inter-day variability were determined by repeated injections (n = 5) of 
independent samples of the different validation standards. The validation standard 
concentrations were 15, 40 and 90 µg/ml representing low, middle and high concentrations 
respectively. Accuracy was assessed by comparing the predicted concentrations of the 
validation standard samples with the nominal 15, 40 and 90 µg/ml concentrations. 
 Limit of detection (LOD) and limit of quantitation (LOQ) 
LOD and LOQ were estimated based on signal-to-noise (S/N) ratio according to ICH 
guidelines by multiplying the estimated noise using Lab Solutions software version 5.42 SP5, 
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Shimadzu Corporation, Japan. The estimated noise was multiplied by 3.3 and 10 for 
determination of LOD and LOQ respectively
 
2.2. Forced degradation studies  
Carnosine was subjected to stress conditions according to ICH guidelines in order to monitor 
whether the assay was stability-indicating. The investigated stress conditions were acid (0.1 
M HCl) at 60oC, base (0.1 M NaOH) at 60oC, oxidising agent (2% v/v H2O2) at room 
temperature and thermal (PBS pH 7.4) at 60oC [13, 14]. The samples were allowed to cool, 
were neutralised (for acid and base samples), filtered and then diluted prior to quantitative 
analysis. All experiments were performed in triplicate. 
2.3. Degradation product identification using electrospray ionisation-mass spectroscopy 
(ESI-MS)  
To identify peaks of the resultant degradation products, freshly prepared carnosine solution 
and NaOH-degraded samples were analysed using Waters Micromass, LCT mass 
spectrometer (Waters Corporation, Lancashire, UK) coupled with a KD Scientific syringe 
pump (KD Scientific, Holliston, Massachusetts, USA). The samples were diluted to 1 µg/ml 
and were introduced by direct injection at 180 µl/h into an electron spray ionisation (ESI) 
source in a positive ionisation mode (capillary voltage -3000V), RF value of 89 and 
desolvation temperature of 300 oC. Data was acquired for 3 min over a 50 to 1000 m/z range. 
Spectra were averaged over the 3 min and processed using MassLynx software (Waters 
Corporation, Lancashire, UK). 
2.4. L-carnosine-phospholipid complex 
Equimolar amounts of L-carnosine and lipoid S75 were dissolved in a hydromethanolic 
solution (30% water-70% methanol), transferred into a 100-ml round bottom flask and 
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refluxed for 1 hours at 40oC and then the solvent was removed by rotary evaporation  in a 
Buchi rotary evaporator (Buchi, Switzerland) [15].  
2.5. Determination of n- octanol/PBS partition coefficient of carnosine 
The partition of L-carnosine between equal volumes of octanol (organic phase) and PBS at 
pH 7.4 (aqueous phase) was determined at 35oC (ocular surface temperature) as previously 
mentioned [16]. The drug concentration in the organic phase was determined by subtracting 
the drug concentration in the aqueous phase before and after distribution using the HPLC 
method described above. The partition coefficient (P) was calculated using equation 3 [17, 
18]: 
E
Einitial
w
o
C
CC
C
CP −==                                                                   [3] 
where Co is the concentration of NTX in n-octanol, Cw is the total concentration of carnosine 
in PBS, and Cinitial and CE are the concentration of L-carnosine in PBS initially and at 
equilibrium respectively. 
3. Results and discussion 
3.1.  HPLC method validation 
The system suitability parameters were found to be within acceptable limits. The retention 
time of L-carnosine under the experimental conditions was 3.8 min and the peak was well 
resolved from the formulation excipients.  An analytical run time of 8 min was sufficient to 
ensure that all excipients / contaminants had eluted. The following validation parameters 
were estimated and evaluated according to the ICH guidelines [12]: 
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3.1.1.  Linearity 
The linearity was assessed by ANOVA analysis using GraphPad Instat, 3.05, USA to 
determine the correlation coefficient (R) and P value. The standard calibration curve was 
linear in the range of 10–100 µg/ml (R > 0.999 and P < 0.0001). Percentage (%) recovery 
± % relative standard deviation (RSD) ranged from 96.2 ± 4.0 to 101.7 ± 1.7 (Table 1). 
LOD and LOQ were estimated to be 0.5 µg/ml and 1 µg/ml respectively. 
3.1.2.   Precision and accuracy 
The precision and accuracy of the method were reported as the relative standard deviation 
(%RSD) and % recovery of the QC samples (Table 2). The intra-day and inter-day precision 
for the three samples were found to be between 0.4 and 2.87%, and 0.44 and 2.5% 
respectively. These values comply with the acceptance criteria of the ICH guidelines [19]. 
3.2. Forced degradation studies 
L-carnosine was subjected to a series of forced degradation cycles for 7 days in order to 
obtain appreciable degradation products that could be resolved on the chromatograms and 
further reflect the ability of the developed method to differentiate between analyte and 
degradation product peaks. The analyte peaks were well resolved from peaks for the reagents 
used and reagent stabilisers (H2O2) as shown in Figure 1.  Percentage recovery values of L-
carnosine under the stress conditions are shown in Figure 2. The drug solution showed slight 
to extensive degradation dependent upon the stress condition used. 
Approximately 30 % of the initial concentration of L-carnosine was lost after exposure to 
strong alkaline conditions for 7 days at 60 °C. Exposure of L-carnosine to a strong acid 
showed moderate degradation. The extent of L-carnosine degradation in PBS was 
significantly less (P < 0.01, unpaired t test) than that in the base or acid solutions.  L-
carnosine showed slight degradation when subjected to an oxidizing agent. Confirmation of 
the degradation products was performed by using 1 mg/ml of pure solution of β-alanine and 
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histidine. The histidine peak eluted at the same retention time of alkaline and acidic 
degradation products at 3.39 min.  However, β-alanine did not show up on the UV detector 
due to absence of chromophores. These findings indicate that the assay was stability 
indicating and the main degradation mechanism of L-carnosine is by hydrolysis of the  both 
peptide bonds forming the constituent amino acids. 
 
3.3. Degradation product identification using electron spray ionisation-mass 
spectroscopy (ESI-MS)  
Mass spectra were generated to determine the molecular weight of the drug and main 
degradation products in solution at 60oC under alkaline conditions (Figure 3A and B). Other 
stressed drug solutions in HCL, PBS and hydrogen peroxide showed insignificant (less than 
10%) degradation as detected with ESI-MS.  
The mass spectra were determined on a LCT- Time of Flight (TOF)-MS system, using ESI in 
negative mode. Under these detection conditions, the sample ionises by interacting with the 
solvent (in this case acetonitrile). The detector can detect negative ions. The results showed 
that L-carnosine and two major ion peaks (histidine and alanine) appeared at 225, 154.1 and 
88.1 m/z respectively. These masses correspond to the negatively charged ion (M-H) of 
carnosine; and its constituent amino acids suggesting that the mechanism of degradation is by 
hydrolytic cleavage of both peptide bonds into the comprising amino acids. 
3.4. Partition coefficient (n- octanol/PBS) of carnosine 
Drug lipid solubility (lipophilicity) is an essential property for drug permeation via lipid 
membranes such as the  corneal epithelium [20]. Drug lipophilicity is related to its chemical 
structure and can be assessed by measuring the partition coefficient (P). The results showed 
that P values of L-carnosine and L-carnosine-phospholipid complex at 35oC (ocular 
temperature)[21]  were 0.026 and 0.55 respectively. The results showed a significant increase 
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(P < 0.001) when L-carnosine was formulated as a phospholipid complex. The estimated P 
value for L-carnosine-phospholipid complex was found to be twenty times greater than that 
for L-carnosine. L-carnosine is a highly hydrophilic drug and delivery it to the eye requires a 
penetration enhancer. Using the L-carnosine-phospholipid complex offers a viable 
alternative. 
Conclusion 
This study investigated the chemical stability of L-carnosine under different stress conditions. 
The main degradation pathway was found to be hydrolysis. Lipophilicity studies showed that 
L-carnosine is hydrophilic and that its permeation through the cornea would be 
predominantly dependent on the epithelium barrier. Lipid-based systems such as 
phospholipid complexes (PC) could improve L-carnosine lipophilicity, impart possible 
permeation enhancing effects and prolong precorneal residence time. Further investigations 
into PC as possible ocular carriers for L-carnosine are underway. 
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Figure 1 HPLC chromatograms of L-carnosine after exposure to stress conditions of heat (at 60 for 7 
days), acid (0.1 M HCl at 60 for 7 days), alkaline (0.1 M Na OH at 60 for 7 days) and hydrogen peroxide 
(2% at ambient conditions for 24 hours). 
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Figure 2 Percentage (%) recovery of L-carnosine after exposure to various stress conditions  
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Figure  3 ESI MS spectra for L-carnosine and canrosine and its degradation products (B) 
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Table 1 Predicted concentrations, % recovery and linear regression parameters for the 
developed analytical method 
 
  
Set number  
Nominal concentration (µg/ml) 
R Slope Intercept 10 20 50 80 100 
1 9.81 20.59 51.91 81.43 101.20 0.9998 34891 43147 
2 9.96 21.05 51.67 80.57 101.06 0.9998 34587 54529 
3 8.78 18.79 50.47 80.07 100.19 0.9998 34989 -7651 
4 9.78 19.41 50.14 80.15 96.05 0.9981 33486 51256 
5 9.65 19.29 50.04 79.95 98.017 0.9991 34072 30212 
Mean 9.62 19.83 50.85 80.43 99.31 0.9994 34405 34299 
% RSD 4.00 3.50 1.70 0.75 1.90 
   % recovery 96.20 99.15 101.70 100.50 99.31 
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Table 2 Precision and accuracy of the validation standard (Results are expressed as 
mean values, n = 5) 
  
  
Nominal concentration (µg/ml) 
Intra-day Inter-day 
15 40 90 15 40 90 
Mean 14.55 40.10 89.40 14.35 38.80 88.50 
% RSD 2.87 1.26 0.40 2.5 1.5 0.44 
% Recovery 97.00 100.25 99.33 95.66 97.00 98.33 
 
 
